Three biosimilar products are now licensed for the treatment of rheumatic diseases in Europe. The European Medicines Agency (EMA) requires that similarity between a biosimilar and its reference product is demonstrated using a rigorous, stepwise process that includes extensive physicochemical and biological analytical testing, non-clinical pharmacology, clinical evaluations, and pharmacovigilance plans. Each

Prof Peter Taylor opened the symposium focussed on optimisation of treatment for rheumatoid arthritis (RA) at each stage of the patient’s journey. Prof…

Targeted biologics have revolutionised the treatment and outlook of patients with inflammatory joint diseases. The combination of high-cost long-term…

This educational symposium was opened by Prof Ernest Choy, who introduced the concept of precision medicine and highlighted the importance of integrating…

Prof Josef Smolen opened the symposium and briefly described the aims of the meeting. Co-host Prof Constantino Pitzalis first discussed the…

Sjögren’s syndrome (SjS) is a chronic, progressive, systemic, human autoimmune disease in which an auto-inflammatory process within the salivary and…

The aim of the present review is to summarise the results from recent clinical studies on the basis of the newly proposed temporal classification of…

People with rheumatoid arthritis (RA) are often under-recognised as a group with elevated risk of cardiovascular (CV) disease and increased morbidity…

Psoriatic arthritis is an inflammatory arthritis which affects the skin and musculoskeletal system. If not diagnosed early and treated effectively it can…

The current goals in the development of novel therapeutics of systemic autoimmune diseases are to develop agents more effective than conventional…